Entries by neurogentx

Muna Therapeutics appoints Dr. Donald Nicholson as Independent Chair of Board of Directors

Industry leader with expertise in building successful biotechnology companies Copenhagen, Denmark and Boston, US 13th September 2021 – Muna Therapeutics (“Muna”), pioneering the development of first-in-class small molecule therapeutics for neurodegenerative diseases, today announced the appointment of Dr. Donald Nicholson, as independent Chair of its Board of Directors. Dr. Nicholson has deep experience across both […]

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases

Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to neurodegeneration and all-in-human validation Copenhagen, […]